Close
Close

AstraZeneca - Ovarian Cancer

Partner

Not provided

Rare Disease

Ovarian Cancer

Sponsor

AstraZeneca

Access Program Information

This is an open-label, single-arm, international, multicenter Multiple Patient Expanded Access Program (MPEAP). The program is designed to provide treatment access to olaparib tablets for patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer without other treatment options or eligible for an olaparib clinical trials.

Contact
Locations

Free Newsletter